Viridian Therapeutics (Viridian Therapeutics) Cash Ratio : 23.47 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Viridian Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Viridian Therapeutics's Cash Ratio for the quarter that ended in Mar. 2024 was 23.47.

Viridian Therapeutics has a Cash Ratio of 23.47. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Viridian Therapeutics's Cash Ratio or its related term are showing as below:

VRDN' s Cash Ratio Range Over the Past 10 Years
Min: 0.73 Med: 7.06 Max: 23.47
Current: 23.47

During the past 12 years, Viridian Therapeutics's highest Cash Ratio was 23.47. The lowest was 0.73. And the median was 7.06.

VRDN's Cash Ratio is ranked better than
94.69% of 1525 companies
in the Biotechnology industry
Industry Median: 2.94 vs VRDN: 23.47

Viridian Therapeutics Cash Ratio Historical Data

The historical data trend for Viridian Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Cash Ratio Chart

Viridian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Ratio

Get a 7-Day Free Trial

2.64

11.96

14.44

12.73

17.92

Viridian Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Ratio	Get a 7-Day Free Trial															12.64	11.67	13.46	17.92	23.47

Competitive Comparison of Viridian Therapeutics's Cash Ratio

For the Biotechnology subindustry, Viridian Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viridian Therapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's Cash Ratio falls into.

Viridian Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Viridian Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	477.37	/	26.635
	=	17.92

Viridian Therapeutics's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )	=	Cash, Cash Equivalents, Marketable Securities	/	Total Current Liabilities
	=	613.187	/	26.127
	=	23.47

Viridian Therapeutics (NAS:VRDN) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.

Viridian Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics (Viridian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (NAS:VRDN) » Definitions » Cash Ratio

Comparable Companies

Traded in Other Exchanges

1S1:Germany

Address

221 Crescent Street, Suite 401, Waltham, MA, USA, 02453

Website

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Executives

Stephen F. Mahoney	director, officer: President and CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	officer: Chief Operating Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sarah Gheuens	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Seth Harmon	officer: See Remarks	C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453
Lara Meisner	officer: General Counsel and Secretary	C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453
Scott Dunseth Myers	director, officer: Chief Executive Officer	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Jonathan Violin	officer: President and COO	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Barrett Katz	officer: Chief Medical Officer	6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301
Fairmount Healthcare Fund Gp Llc	director, other: See Remarks	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Carrie Melvin	officer: COO	C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453
Frazier Life Sciences Public Fund, L.p.	10 percent owner	TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101
L.p. Fhmlsp,	10 percent owner	C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Fhmlsp, L.l.c.	10 percent owner	C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Kristian Humer	officer: CFO and CBO	C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301
Jennifer K. Moses	director	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709